Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study.
OBJECTIVE
To determine the effectiveness of treatment with conjugated equine estrogens (CEE) or with CEE combined with progestin (CEE + P) on age-related macular degeneration (AMD).


METHODS
In an ancillary study to the Women's Health Initiative clinical trial of hormone therapy, 4262 women 65 years and older underwent fundus photography for the determination of AMD. Participants were recruited from April 2000 to June 2002 at 21 clinical sites an average of 5 years after randomization. Participants were randomized to treatment with CEE, CEE + P, or placebo. Participants had been treated for an average of 5 years at the ophthalmic evaluation for AMD.


RESULTS
The overall prevalence of any AMD was 21.0%. No association was found between CEE + P (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.75-1.11) or CEE alone (OR, 0.98; 95% CI, 0.78-1.25) and early-stage AMD. The CEE + P was associated with a reduced risk of soft drusen (OR, 0.83; 95% CI, 0.68-1.00) after adjustment for covariates and with a reduced risk of neovascular AMD (OR, 0.29; 95% CI, 0.09-0.92).


CONCLUSIONS
Treatment with CEE alone or CEE + P does not affect early- or late-stage AMD. Treatment with CEE + P may reduce the risk of soft drusen or neovascular AMD.
Haan
Mary N
MN
Department of Epidemiology, University of Michigan, 611 Church Street, Ann Arbor, MI 48104, USA. mnhaan@umich.edu
Klein
Ronald
R
Klein
Barbara E
BE
Deng
Yingzi
Y
Blythe
Lynn K
LK
Seddon
Johanna M
JM
Musch
David C
DC
Kuller
Lewis H
LH
Hyman
Leslie G
LG
Wallace
Robert B
RB
D000368:Aged; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D016017:Odds Ratio; D010781:Photography; D017698:Postmenopause; D015995:Prevalence; D011374:Progesterone / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D014481:United States / Q000453:epidemiology; D016387:Women's Health
D004967:Estrogens; D004966:Estrogens, Conjugated (USP); C112940:Progest; D011374:Progesterone